| Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA) (NCT07714616) | Eurofarma Laboratorios S.A. | 2027-05-31 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. (NCT07529977) | Eurofarma Laboratorios S.A. | 2027-01-31 |
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) (NCT07303322) | Eurofarma Laboratorios S.A. | 2027-01-01 |
| iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (NCT06560333) | Eurofarma Laboratorios S.A. | 2026-11-30 |
| Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO) (NCT06546735) | Eurofarma Laboratorios S.A. | 2026-11-30 |
| Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension (NCT06608472) | Eurofarma Laboratorios S.A. | 2026-11-30 |
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) (NCT07318350) | Eurofarma Laboratorios S.A. | 2026-10-01 |
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (NCT06234345) | Eurofarma Laboratorios S.A. | 2026-09-01 |
| Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin (NCT07057479) | Eurofarma Laboratorios S.A. | 2026-09-01 |
| Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil (NCT05735431) | Eurofarma Laboratorios S.A. | 2026-06-01 |
| Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil (NCT05683574) | Eurofarma Laboratorios S.A. | 2026-05-30 |
| A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight (NCT05209984) | Eurofarma Laboratorios S.A. | 2026-04-01 |
| Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy (NCT06715462) | Eurofarma Laboratorios S.A. | 2026-04-01 |
| Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (NCT05637710) | Eurofarma Laboratorios S.A. | 2026-03-01 |
| Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris (NCT06905210) | Eurofarma Laboratorios S.A. | 2026-03-01 |
| Evaluation of the EF192B Protection Versus No Treatment (NCT06752460) | Eurofarma Laboratorios S.A. | 2025-08-31 |
| Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment (NCT05118672) | Eurofarma Laboratorios S.A. | 2025-03-26 |
| Evaluation of the Protection of a Liquid Bandage (NCT05888311) | Eurofarma Laboratorios S.A. | 2025-02-18 |
| Evaluation of Skin Irritancy and Sensitization of a Liquid Bandage (NCT05876546) | Eurofarma Laboratorios S.A. | 2025-01-31 |
| Assessment of EF192A Potential Sensitization and Accumulated and Primary Irritability in Controlled/Maximized Conditions (NCT06731062) | Eurofarma Laboratorios S.A. | 2025-01-20 |
| Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity (NCT05209997) | Eurofarma Laboratorios S.A. | 2024-12-01 |
| Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children (NCT05214911) | Eurofarma Laboratorios S.A. | 2024-07-08 |
| Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction (NCT05081102) | Eurofarma Laboratorios S.A. | 2024-03-27 |
| Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction (NCT04972292) | Eurofarma Laboratorios S.A. | 2023-11-08 |
| A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment (NCT04233190) | Eurofarma Laboratorios S.A. | 2023-04-19 |
| Treatment of Androgenetic Alopecia in Men for 24 Weeks (NCT04721548) | Eurofarma Laboratorios S.A. | 2023-03-02 |
| Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine (NCT04384367) | Eurofarma Laboratorios S.A. | 2022-12-30 |
| Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer (NCT03936933) | Eurofarma Laboratorios S.A. | 2020-10-30 |
| Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer (NCT03936218) | Eurofarma Laboratorios S.A. | 2020-09-30 |
| Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis (NCT02988778) | Eurofarma Laboratorios S.A. | 2019-10-08 |
| The Effect of a Multivitamin in the Treatment of Memory Loss in Postmenopausal Women (NCT03835325) | Eurofarma Laboratorios S.A. | 2019-01-23 |
| A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study (NCT03936192) | Eurofarma Laboratorios S.A. | 2019-01-01 |
| Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy (NCT02768714) | Eurofarma Laboratorios S.A. | 2018-01-01 |